IP Library Granted Patent US 7,473,773
Granted Patent B2
US 7,473,773 · App. 11/031,487 · Granted Jan 6, 2009

Determination of hepatitis C virus genotype

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,473,773
App. No.
11/031,487
Granted
Jan 6, 2009
Kind
B2
Abstract

The present invention provides compositions and methods for the detection and characterization of HCV sequences. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, to determine HCV genotype.

Claims (31)

1. A method for determining the genotype of hepatitis C virus in a sample comprising;

a) providing;

i) a sample from a subject, wherein said sample is suspected of containing hepatitis C virus, and

ii) two or more probe sets, wherein each of probe sets is configured for detecting a single nucleotide polymorphism in a 5′ UTR sequence of HCV, and

b) contacting said sample with said two or more probe sets under conditions such that at least partial genotype information for each of said single nucleotide polymorphisms is determined thereby generating a 5′ UTR genotype profile, wherein said 5′ UTR genotype profile comprises at least partial genotype information for single nucleotide polymorphisms located in at least two of the following positions: −245, −167, −163, −155, −144/5, −118, and −80; wherein said positions are found in SEQ ID NOs 64, 65, 66, 67, 68 and 69 as shown in FIG. 10 , and wherein said 5′ UTR genotype profile is sufficient to genotype said hepatitis C virus.

2. The method of claim 1 , further comprising c) genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I, II, IV, V, or VI.

3. The method of claim 2 , wherein said genotyping classifies said hepatitis C virus as being Genotype I, IV or V.

4. The method of claim 1 , wherein said two or more probe sets comprise invasive cleavage structure type probes.

5. The method of claim 1 , wherein each probe set comprises a first oligonucleotide, wherein said first oligonucleotide comprises a 5′ portion and a 3′ portion, wherein said 3′ portion is configured to hybridize to said 5′ UTR sequence of HCV, and wherein said 5′ portion is configured to not hybridize to said 5′ UTR sequence of HCV.

6. The method of claim 1 , wherein each probe set comprises a second oligonucleotide, wherein said second oligonucleotide comprises a 5′ portion and a 3′ portion, wherein said 5′ portion is configured to hybridize to said 5′ UTR sequence of HCV, and wherein said 3′ portion is configured to not hybridize to said 5′ UTR sequence of HCV.

7. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) an A at position −163, and ii) no C at position −144, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

8. The method of claim 7 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167, or a T at position −167.

9. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) an A at position −163, and ii) a T at position −80, wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

10. The method of claim 9 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167, or a T a position −167.

11. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) an A at position −163, and ii) a C at position −72, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

12. The method of claim 11 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167, or a T a position −167.

13. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −122, and ii) no C at position −144, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

14. The method of claim 13 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167.

15. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −122, and ii) a T at position −80, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

16. The method of claim 15 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167.

17. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −122, and ii) a C at position −72, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype I.

18. The method of claim 17 , wherein said 5′ UTR genotype profile further comprises: iii) no C at position −167.

19. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) an A at position −132, and ii) a G at position −163, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype II.

20. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −245, and ii) a C at position −167, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype IV.

21. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −245, and ii) an A at position −118, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype IV.

22. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −167, ii) a G at position −163, and iii) a C at position −155, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype V.

23. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a C at position −122, and ii) a G at position −117, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype V.

24. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a G at position −117, and ii) a C at position −80, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype VI.

25. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) an A at position −118, and ii) a C at position −80, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype VI.

26. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −122, and ii) a C at position −80, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype VI.

27. The method of claim 1 , wherein said 5′ UTR genotype profile comprises: i) a T at position −122, and ii) a T at position −72, and wherein the method further comprises genotyping said hepatitis C virus based on said 5′ UTR genotype profile as Genotype VI.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →